Market research
OPT.AU Opthea Limited
AU AUD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- 0.1
- Dividend yield
- Not available
- Beta
- 1.53
Profile
Company facts
- Exchange
- AU
- Currency
- AUD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- AU000000OPT2
- Market cap
- 18M
- P/E ratio
- Not available
- Analyst target
- 0.1
- Dividend yield
- Not available
- Beta
- 1.53
About
About Opthea Limited
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the OPT.AU discussion.
5 years, 5 months ago
Opthea Limited is currently in a long term downtrend where the price is trading 27.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Opthea Limited's total revenue rose by 15.1% to $314K since the same quarter in the previous year.
Its net income has dropped by 359.1% to $-35M since the same quarter in the previous year.
Finally, its free cash flow fell by 733.9% to $-12M since the same quarter in the previous year.
Based on the above factors, Opthea Limited gets an overall score of 2/5.